[Smilodon]

Don't know how many of you have already seen this. Thought it might be useful here. (from AAMC site)
************************************************** *****


Hepatitis C - The Silent Killer
Can Medical Cannabis Help?

Jay R. Cavanaugh, PhD

Hepatitis C (HCV) is a blood borne pathogen that presently infects some four to eight million Americans making it the leading blood borne virus in America. HCV is the primary cause of liver cancer and cirrhosis and kills over 10,000 Americans each year. Hepatitis C is the leading factor in patients who require liver transplant. Some 80% of those who contract HCV will go on to develop chronic infection and 20% of these will develop cirrhosis, liver cancer, or liver failure. A slim 20% of those infected will eliminate the virus from their body on their own.

Patients can contract Hepatitis C from using shared needles, accidental needle stick injuries, blood transfusions (prior to 1990), and to a minor degree from unprotected sex. HCV can be transmitted from an infected tattoo needle, dental instruments, or tools used in commercial nail care. Anything that assists the transfer of HCV infected blood from one person to another can be a vector. The blood of a patient with HCV can be highly contagious and precautions should be taken to not come in contact with it.

Hepatitis C usually produces no early symptoms. The disease can go unrecognized for decades. This is why HCV is termed a "silent killer". During the decades of quiescence the virus can continue to slowly destroy liver cells without the patient having any idea this is happening. The following groups are considered "high risk" and should be tested for the virus:

1. IV drug users who have shared needles
2. Sexual partners of HCV patients
3. Family members of HCV patients
4. Individuals receiving a blood transfusion prior to 1990
5. Patients who undergo dialysis
6. Individuals with tattoos or who have their nails frequently done
7. Individuals who have suffered a needle stick incident
8. Patients who have been diagnosed with any liver disease

Symptoms:

While patients are generally unaware of HCV infection for many years, some 80% may eventually develop symptoms which can include:

1. Fatigue and malaise
2. Loss of appetite
3. Weight loss
4. Jaundice
5. Joint pain and headache
6. Fluid retention in the abdomen (ascites)
7. Nausea and vomiting
8. Itching

Diagnosis:

Diagnosis begins with a simple history and blood test. The history looks at risk factors and symptoms. The blood test is generally to measure both liver enzymes (produced when the liver is damaged) and to detect antibodies to the Hepatitis C virus and/or to quantify the amount of virus present in the blood stream. The amount of virus is called the "titer" and is determined using the polymerase chain reaction (PCR) with HCV "primers". Additional blood tests can determine the specific strain of virus present (some strains are more pathogenic than others). A physical examination will be conducted that includes probing the liver for enlargement and looking for other possible factors such as swelling in the legs and feet and jaundice.

Prior to the initiation of treatment, it is common practice to conduct additional tests to more closely ascertain the status of the liver and the need for treatment. A liver scan using radioactive isotopes and X-ray can highlight liver structures and blood flow. A CAT scan may be conducted to look for tumors or blockage. The definitive diagnostic procedure is a liver biopsy where small samples of the liver are extracted through an office surgical procedure and examined for pathology. A liver biopsy taken from different quadrants of the liver can reveal hepatocarcinoma (liver cancer), fatty deposits, and cirrhosis (scarring).

Why is the liver important?

The liver is the largest internal organ. It is within the liver that medications and toxins are neutralized, metabolized, and eliminated (with the help of the kidneys). The liver is the site of sugar storage (glycogen) and plays a vital role in maintaining normal blood sugar along with the pancreas. The body’s fluid balance and blood clotting are largely controlled by the liver as is the processing of proteins. Bile produced in the liver aides in the digestion of food. Most noticeable is the role of the liver in energy production which is why fatigue is so common in liver disease.

Treatment for Hepatitis C:

Current therapy focuses on the subcutaneous administration of a combination of Interferon alpha (an immunomodulator) and the anti-viral drug Ribavirin. Depending upon the type of Interferon used, dosing can be one to three times a week for six to 18 months. Approximately 50% of those treated respond although it is not yet known how long the response might last. Combination drug therapy is usually not attempted when there is no sign of liver damage as determined by histopathology following biopsy. Drug therapy is also contraindicated when patients have long standing problems with depression or heart disease. The major side effects of the therapy include flu like symptoms, joint pain, nausea, anemia and depression. The decision to undergo combination therapy is a very serious one and should be done only under the supervision of a qualified and experienced physician. HCV patients with liver impairment must avoid hepatotoxins, particularly alcohol and acetaminophen (Tylenol).

Alcohol is a key toxin that damages the liver. Normal healthy adults are advised to drink no more than two drinks a day for men and one for women. With liver disease that recommendation drops to zero. Yet, many in the general population and the HCV population are heavy drinkers. Cannabis can be an effective harm reduction agent for those with alcohol problems along with therapy and self help.

Long term Complications of Hepatitis C:

Cirrhosis - As liver cells are destroyed by virally induced inflammation, they can be replaced by scar tissue (hence the name) which does not function to conduct normal liver functions. Cirrhosis is chronic and progressive. Cirrhosis occurs in approximately 20% of all HCV cases and may lead to cancer. The course of cirrhosis is variable but usually includes fluid build up in the abdomen (ascites), portal hypertension, and esophageal varices (swollen blood vessels). Treatment is limited to alleviating symptoms. Fluid may be periodically drained and medicines provided to reduce hypertension and fluid imbalances. Cirrhosis can cause uncontrolled bleeding, coma, and death.

Hepatocellular carcinoma (liver cancer) - Constant cell death and division caused by HCV can lead to tumors in 1-5% of all patients. Liver cancer is curable only in its earliest stages if it is contained within the liver in an area approachable by surgery. In other cases various treatments can be used including cryotherapy (freezing) and ethanol ablation. Chemotherapy, at present, is not usually effective with liver tumor. Liver cancer is generally terminal with treatment limited to symptomatic relief and improving the quality and length of life.

Liver failure and transplantation - As HCV destroys liver tissue; liver function can be increasingly compromised leading to failure. As the liver fails toxins can circulate that harm other organs and effect perception and behavior. Medications are not metabolized normally and have an increased risk of side effects and adverse reaction. Essential clotting factors may not be produced leading to uncontrolled internal bleeding. Complete failure results in coma and death. Patients with cirrhosis, cancer, and/or liver failure can sometimes be helped by a liver transplant. Hard to come by, transplants are usually restricted to those cases where they may materially help. Patients who continue to abuse alcohol or drugs are often excluded from transplant waiting lists as are those whose cancer has spread beyond the liver. Others excluded are surgical risks (usually those with cardiac disease) and those with compromised immune systems. Patients survive transplantation in nearly 80% of trials although continued use of immunosuppressants is needed.



Can medical cannabis help?

The short answer is yes. The primary role of cannabis is to stimulate appetite, reduce nausea and vomiting, and treat joint pain. This role is applicable to HCV patients undergoing chemotherapy, those with cancer or cirrhosis, and those with joint pain and headache. Cannabis is far less toxic than other medications that might be prescribed for these conditions and where liver impairment is concerned, it is vital to avoid toxicity. Cannabis may help alleviate the depression often produced by chronic illness and by combination drug therapy. Additionally, cannabis based food products may provide needed extra nutrition without taxing the liver. Using cannabis in place of alcohol is an established harm reduction technique particularly important when liver disease is present.

Perhaps more important but still unknown is the possibility that some of the chemical components of cannabis (the Cannabinoids) may actually reduce liver inflammation and slow the progression of both cirrhosis and Hepatocellular carcinoma. The cannabinoids have been shown to be powerful anti-inflammatories and anti-oxidants. They have also been shown to have anti-neoplastic activity, at least in gliomas (a form of brain cancer). Cannabinoids both slow programmed cell death (apoptosis) in normal cells while accelerating apoptosis in cancer cells.

Since cannabis is nontoxic it might as well be tried, particularly in patients who have chronic progressive disease that is likely to result in death. It is important to point out that whole cannabis (whether smoked, vaporized, elixir, or in food products) is preferable to Marinol. The prescription drug Marinol contains only one cannabinoid (THC) and lacks the other healing properties of the whole herb and its extracts. Dosing is up to the physician and patient. Usually patients "self-titrate" or use only what they feel they need for symptomatic relief. This may be a mistake as the protective effects of cannabis are best achieved with a steady state minimal blood level of Cannabinoids. It is recommended that a base line level of Cannabinoids be maintained with regular doses of oral cannabis products and the smoked or vaporized form of cannabis used for acute symptomatic relief.

[Ff99l1]

Originally Posted by Smilodon

Don't know how many of you have already seen this. Thought it might be useful here. (from AAMC site)
************************************************** *****


Hepatitis C - The Silent Killer
Can Medical Cannabis Help?

Jay R. Cavanaugh, PhD

Hepatitis C (HCV) is a blood borne pathogen that presently infects some four to eight million Americans making it the leading blood borne virus in America. HCV is the primary cause of liver cancer and cirrhosis and kills over 10,000 Americans each year. Hepatitis C is the leading factor in patients who require liver transplant. Some 80% of those who contract HCV will go on to develop chronic infection and 20% of these will develop cirrhosis, liver cancer, or liver failure. A slim 20% of those infected will eliminate the virus from their body on their own.

Patients can contract Hepatitis C from using shared needles, accidental needle stick injuries, blood transfusions (prior to 1990), and to a minor degree from unprotected sex. HCV can be transmitted from an infected tattoo needle, dental instruments, or tools used in commercial nail care. Anything that assists the transfer of HCV infected blood from one person to another can be a vector. The blood of a patient with HCV can be highly contagious and precautions should be taken to not come in contact with it.

Hepatitis C usually produces no early symptoms. The disease can go unrecognized for decades. This is why HCV is termed a "silent killer". During the decades of quiescence the virus can continue to slowly destroy liver cells without the patient having any idea this is happening. The following groups are considered "high risk" and should be tested for the virus:

1. IV drug users who have shared needles
2. Sexual partners of HCV patients
3. Family members of HCV patients
4. Individuals receiving a blood transfusion prior to 1990
5. Patients who undergo dialysis
6. Individuals with tattoos or who have their nails frequently done
7. Individuals who have suffered a needle stick incident
8. Patients who have been diagnosed with any liver disease

Symptoms:

While patients are generally unaware of HCV infection for many years, some 80% may eventually develop symptoms which can include:

1. Fatigue and malaise
2. Loss of appetite
3. Weight loss
4. Jaundice
5. Joint pain and headache
6. Fluid retention in the abdomen (ascites)
7. Nausea and vomiting
8. Itching

Diagnosis:

Diagnosis begins with a simple history and blood test. The history looks at risk factors and symptoms. The blood test is generally to measure both liver enzymes (produced when the liver is damaged) and to detect antibodies to the Hepatitis C virus and/or to quantify the amount of virus present in the blood stream. The amount of virus is called the "titer" and is determined using the polymerase chain reaction (PCR) with HCV "primers". Additional blood tests can determine the specific strain of virus present (some strains are more pathogenic than others). A physical examination will be conducted that includes probing the liver for enlargement and looking for other possible factors such as swelling in the legs and feet and jaundice.

Prior to the initiation of treatment, it is common practice to conduct additional tests to more closely ascertain the status of the liver and the need for treatment. A liver scan using radioactive isotopes and X-ray can highlight liver structures and blood flow. A CAT scan may be conducted to look for tumors or blockage. The definitive diagnostic procedure is a liver biopsy where small samples of the liver are extracted through an office surgical procedure and examined for pathology. A liver biopsy taken from different quadrants of the liver can reveal hepatocarcinoma (liver cancer), fatty deposits, and cirrhosis (scarring).

Why is the liver important?

The liver is the largest internal organ. It is within the liver that medications and toxins are neutralized, metabolized, and eliminated (with the help of the kidneys). The liver is the site of sugar storage (glycogen) and plays a vital role in maintaining normal blood sugar along with the pancreas. The body’s fluid balance and blood clotting are largely controlled by the liver as is the processing of proteins. Bile produced in the liver aides in the digestion of food. Most noticeable is the role of the liver in energy production which is why fatigue is so common in liver disease.

Treatment for Hepatitis C:

Current therapy focuses on the subcutaneous administration of a combination of Interferon alpha (an immunomodulator) and the anti-viral drug Ribavirin. Depending upon the type of Interferon used, dosing can be one to three times a week for six to 18 months. Approximately 50% of those treated respond although it is not yet known how long the response might last. Combination drug therapy is usually not attempted when there is no sign of liver damage as determined by histopathology following biopsy. Drug therapy is also contraindicated when patients have long standing problems with depression or heart disease. The major side effects of the therapy include flu like symptoms, joint pain, nausea, anemia and depression. The decision to undergo combination therapy is a very serious one and should be done only under the supervision of a qualified and experienced physician. HCV patients with liver impairment must avoid hepatotoxins, particularly alcohol and acetaminophen (Tylenol).

Alcohol is a key toxin that damages the liver. Normal healthy adults are advised to drink no more than two drinks a day for men and one for women. With liver disease that recommendation drops to zero. Yet, many in the general population and the HCV population are heavy drinkers. Cannabis can be an effective harm reduction agent for those with alcohol problems along with therapy and self help.

Long term Complications of Hepatitis C:

Cirrhosis - As liver cells are destroyed by virally induced inflammation, they can be replaced by scar tissue (hence the name) which does not function to conduct normal liver functions. Cirrhosis is chronic and progressive. Cirrhosis occurs in approximately 20% of all HCV cases and may lead to cancer. The course of cirrhosis is variable but usually includes fluid build up in the abdomen (ascites), portal hypertension, and esophageal varices (swollen blood vessels). Treatment is limited to alleviating symptoms. Fluid may be periodically drained and medicines provided to reduce hypertension and fluid imbalances. Cirrhosis can cause uncontrolled bleeding, coma, and death.

Hepatocellular carcinoma (liver cancer) - Constant cell death and division caused by HCV can lead to tumors in 1-5% of all patients. Liver cancer is curable only in its earliest stages if it is contained within the liver in an area approachable by surgery. In other cases various treatments can be used including cryotherapy (freezing) and ethanol ablation. Chemotherapy, at present, is not usually effective with liver tumor. Liver cancer is generally terminal with treatment limited to symptomatic relief and improving the quality and length of life.

Liver failure and transplantation - As HCV destroys liver tissue; liver function can be increasingly compromised leading to failure. As the liver fails toxins can circulate that harm other organs and effect perception and behavior. Medications are not metabolized normally and have an increased risk of side effects and adverse reaction. Essential clotting factors may not be produced leading to uncontrolled internal bleeding. Complete failure results in coma and death. Patients with cirrhosis, cancer, and/or liver failure can sometimes be helped by a liver transplant. Hard to come by, transplants are usually restricted to those cases where they may materially help. Patients who continue to abuse alcohol or drugs are often excluded from transplant waiting lists as are those whose cancer has spread beyond the liver. Others excluded are surgical risks (usually those with cardiac disease) and those with compromised immune systems. Patients survive transplantation in nearly 80% of trials although continued use of immunosuppressants is needed.



Can medical cannabis help?

The short answer is yes. The primary role of cannabis is to stimulate appetite, reduce nausea and vomiting, and treat joint pain. This role is applicable to HCV patients undergoing chemotherapy, those with cancer or cirrhosis, and those with joint pain and headache. Cannabis is far less toxic than other medications that might be prescribed for these conditions and where liver impairment is concerned, it is vital to avoid toxicity. Cannabis may help alleviate the depression often produced by chronic illness and by combination drug therapy. Additionally, cannabis based food products may provide needed extra nutrition without taxing the liver. Using cannabis in place of alcohol is an established harm reduction technique particularly important when liver disease is present.

Perhaps more important but still unknown is the possibility that some of the chemical components of cannabis (the Cannabinoids) may actually reduce liver inflammation and slow the progression of both cirrhosis and Hepatocellular carcinoma. The cannabinoids have been shown to be powerful anti-inflammatories and anti-oxidants. They have also been shown to have anti-neoplastic activity, at least in gliomas (a form of brain cancer). Cannabinoids both slow programmed cell death (apoptosis) in normal cells while accelerating apoptosis in cancer cells.

Since cannabis is nontoxic it might as well be tried, particularly in patients who have chronic progressive disease that is likely to result in death. It is important to point out that whole cannabis (whether smoked, vaporized, elixir, or in food products) is preferable to Marinol. The prescription drug Marinol contains only one cannabinoid (THC) and lacks the other healing properties of the whole herb and its extracts. Dosing is up to the physician and patient. Usually patients "self-titrate" or use only what they feel they need for symptomatic relief. This may be a mistake as the protective effects of cannabis are best achieved with a steady state minimal blood level of Cannabinoids. It is recommended that a base line level of Cannabinoids be maintained with regular doses of oral cannabis products and the smoked or vaporized form of cannabis used for acute symptomatic relief.

Thank You very much for this post. Gary from westlake

[420Jen]

Thank you for the post. I have seen first hand the way mm can help with HepC. My husband was very sick until he started using mm with his HepC treatments. After his treatment his docter said he had never seen such remarkable results in a patient. We know we owe it all to mm.

[Mindfury]

Originally Posted by Smilodon

Don't know how many of you have already seen this. Thought it might be useful here. (from AAMC site)
************************************************** *****


Hepatitis C - The Silent Killer
Can Medical Cannabis Help?

Jay R. Cavanaugh, PhD

Hepatitis C (HCV) is a blood borne pathogen that presently infects some four to eight million Americans making it the leading blood borne virus in America. HCV is the primary cause of liver cancer and cirrhosis and kills over 10,000 Americans each year. Hepatitis C is the leading factor in patients who require liver transplant. Some 80% of those who contract HCV will go on to develop chronic infection and 20% of these will develop cirrhosis, liver cancer, or liver failure. A slim 20% of those infected will eliminate the virus from their body on their own.

Patients can contract Hepatitis C from using shared needles, accidental needle stick injuries, blood transfusions (prior to 1990), and to a minor degree from unprotected sex. HCV can be transmitted from an infected tattoo needle, dental instruments, or tools used in commercial nail care. Anything that assists the transfer of HCV infected blood from one person to another can be a vector. The blood of a patient with HCV can be highly contagious and precautions should be taken to not come in contact with it.

Hepatitis C usually produces no early symptoms. The disease can go unrecognized for decades. This is why HCV is termed a "silent killer". During the decades of quiescence the virus can continue to slowly destroy liver cells without the patient having any idea this is happening. The following groups are considered "high risk" and should be tested for the virus:

1. IV drug users who have shared needles
2. Sexual partners of HCV patients
3. Family members of HCV patients
4. Individuals receiving a blood transfusion prior to 1990
5. Patients who undergo dialysis
6. Individuals with tattoos or who have their nails frequently done
7. Individuals who have suffered a needle stick incident
8. Patients who have been diagnosed with any liver disease

Symptoms:

While patients are generally unaware of HCV infection for many years, some 80% may eventually develop symptoms which can include:

1. Fatigue and malaise
2. Loss of appetite
3. Weight loss
4. Jaundice
5. Joint pain and headache
6. Fluid retention in the abdomen (ascites)
7. Nausea and vomiting
8. Itching

Diagnosis:

Diagnosis begins with a simple history and blood test. The history looks at risk factors and symptoms. The blood test is generally to measure both liver enzymes (produced when the liver is damaged) and to detect antibodies to the Hepatitis C virus and/or to quantify the amount of virus present in the blood stream. The amount of virus is called the "titer" and is determined using the polymerase chain reaction (PCR) with HCV "primers". Additional blood tests can determine the specific strain of virus present (some strains are more pathogenic than others). A physical examination will be conducted that includes probing the liver for enlargement and looking for other possible factors such as swelling in the legs and feet and jaundice.

Prior to the initiation of treatment, it is common practice to conduct additional tests to more closely ascertain the status of the liver and the need for treatment. A liver scan using radioactive isotopes and X-ray can highlight liver structures and blood flow. A CAT scan may be conducted to look for tumors or blockage. The definitive diagnostic procedure is a liver biopsy where small samples of the liver are extracted through an office surgical procedure and examined for pathology. A liver biopsy taken from different quadrants of the liver can reveal hepatocarcinoma (liver cancer), fatty deposits, and cirrhosis (scarring).

Why is the liver important?

The liver is the largest internal organ. It is within the liver that medications and toxins are neutralized, metabolized, and eliminated (with the help of the kidneys). The liver is the site of sugar storage (glycogen) and plays a vital role in maintaining normal blood sugar along with the pancreas. The body’s fluid balance and blood clotting are largely controlled by the liver as is the processing of proteins. Bile produced in the liver aides in the digestion of food. Most noticeable is the role of the liver in energy production which is why fatigue is so common in liver disease.

Treatment for Hepatitis C:

Current therapy focuses on the subcutaneous administration of a combination of Interferon alpha (an immunomodulator) and the anti-viral drug Ribavirin. Depending upon the type of Interferon used, dosing can be one to three times a week for six to 18 months. Approximately 50% of those treated respond although it is not yet known how long the response might last. Combination drug therapy is usually not attempted when there is no sign of liver damage as determined by histopathology following biopsy. Drug therapy is also contraindicated when patients have long standing problems with depression or heart disease. The major side effects of the therapy include flu like symptoms, joint pain, nausea, anemia and depression. The decision to undergo combination therapy is a very serious one and should be done only under the supervision of a qualified and experienced physician. HCV patients with liver impairment must avoid hepatotoxins, particularly alcohol and acetaminophen (Tylenol).

Alcohol is a key toxin that damages the liver. Normal healthy adults are advised to drink no more than two drinks a day for men and one for women. With liver disease that recommendation drops to zero. Yet, many in the general population and the HCV population are heavy drinkers. Cannabis can be an effective harm reduction agent for those with alcohol problems along with therapy and self help.

Long term Complications of Hepatitis C:

Cirrhosis - As liver cells are destroyed by virally induced inflammation, they can be replaced by scar tissue (hence the name) which does not function to conduct normal liver functions. Cirrhosis is chronic and progressive. Cirrhosis occurs in approximately 20% of all HCV cases and may lead to cancer. The course of cirrhosis is variable but usually includes fluid build up in the abdomen (ascites), portal hypertension, and esophageal varices (swollen blood vessels). Treatment is limited to alleviating symptoms. Fluid may be periodically drained and medicines provided to reduce hypertension and fluid imbalances. Cirrhosis can cause uncontrolled bleeding, coma, and death.

Hepatocellular carcinoma (liver cancer) - Constant cell death and division caused by HCV can lead to tumors in 1-5% of all patients. Liver cancer is curable only in its earliest stages if it is contained within the liver in an area approachable by surgery. In other cases various treatments can be used including cryotherapy (freezing) and ethanol ablation. Chemotherapy, at present, is not usually effective with liver tumor. Liver cancer is generally terminal with treatment limited to symptomatic relief and improving the quality and length of life.

Liver failure and transplantation - As HCV destroys liver tissue; liver function can be increasingly compromised leading to failure. As the liver fails toxins can circulate that harm other organs and effect perception and behavior. Medications are not metabolized normally and have an increased risk of side effects and adverse reaction. Essential clotting factors may not be produced leading to uncontrolled internal bleeding. Complete failure results in coma and death. Patients with cirrhosis, cancer, and/or liver failure can sometimes be helped by a liver transplant. Hard to come by, transplants are usually restricted to those cases where they may materially help. Patients who continue to abuse alcohol or drugs are often excluded from transplant waiting lists as are those whose cancer has spread beyond the liver. Others excluded are surgical risks (usually those with cardiac disease) and those with compromised immune systems. Patients survive transplantation in nearly 80% of trials although continued use of immunosuppressants is needed.



Can medical cannabis help?

The short answer is yes. The primary role of cannabis is to stimulate appetite, reduce nausea and vomiting, and treat joint pain. This role is applicable to HCV patients undergoing chemotherapy, those with cancer or cirrhosis, and those with joint pain and headache. Cannabis is far less toxic than other medications that might be prescribed for these conditions and where liver impairment is concerned, it is vital to avoid toxicity. Cannabis may help alleviate the depression often produced by chronic illness and by combination drug therapy. Additionally, cannabis based food products may provide needed extra nutrition without taxing the liver. Using cannabis in place of alcohol is an established harm reduction technique particularly important when liver disease is present.

Perhaps more important but still unknown is the possibility that some of the chemical components of cannabis (the Cannabinoids) may actually reduce liver inflammation and slow the progression of both cirrhosis and Hepatocellular carcinoma. The cannabinoids have been shown to be powerful anti-inflammatories and anti-oxidants. They have also been shown to have anti-neoplastic activity, at least in gliomas (a form of brain cancer). Cannabinoids both slow programmed cell death (apoptosis) in normal cells while accelerating apoptosis in cancer cells.

Since cannabis is nontoxic it might as well be tried, particularly in patients who have chronic progressive disease that is likely to result in death. It is important to point out that whole cannabis (whether smoked, vaporized, elixir, or in food products) is preferable to Marinol. The prescription drug Marinol contains only one cannabinoid (THC) and lacks the other healing properties of the whole herb and its extracts. Dosing is up to the physician and patient. Usually patients "self-titrate" or use only what they feel they need for symptomatic relief. This may be a mistake as the protective effects of cannabis are best achieved with a steady state minimal blood level of Cannabinoids. It is recommended that a base line level of Cannabinoids be maintained with regular doses of oral cannabis products and the smoked or vaporized form of cannabis used for acute symptomatic relief.

Thanks for the info on the post. I'm not sure what stage it is at, but my liver hurts everyday , cept for when i was at the MNG, but i attribute that to a combo of the edibles and the all lovely people that were there.I can say that some sativas certainly help with the fatigue factor, and the appetite/joint pain aswell. it doesnt do much for the itching. Although i havent had treatment yet, i'm 1000% tha MMJ will be a benefit.type 1 is the most non reactive strain(30% success rate), and the fact that i have a rare blood type ab- has certainly changed my outlook/plans for me. MMJ definatly will help treat some of the symptoms, and more importantly may help to keep you alive from the side effects(severe depression) of those toxic drugs they "treat" you with.
Peace

[Smilodon]

My M.D. rec is for Hepatitis C, depression and insomnia. MMJ has helped tremendously. I used to spend 12 hours a day online, never moving, too fatigued and depressed to move. Since mmj I am going places (MnG for instance) and getting way more exercise. I am sleeping and rarely have a moody thought.

There is no way for me to adequately express my gratitude that mmj is a option. MMJ not only is dealing with the Hep C, but also my post herpetic neuropathy and diabetes.

[Mindfury]

I guess i can' have any fun now.

"Daily cannabis use increases the risk of liver fibrosis in patients with hepatitis C"

That could explain a few things.


http://www.hepatitis-central.com/mt/...f_fibrosi.html


f-it maybe i should just go stick another needle in my arm like my **** of a ex told me this morning, amongst other things.

peace?

[ebzgotfiyah]

are they beginin to use medical weed for everthin

[LaMaida1977]

Acute depression, fatigue, apathy & slight fever often accompany hcv. Mj can alliviate all of the above. Check you fibrosis level, if it is low you have no problem. I would like a more recent study to be done on this as there are too many variables in the above study. IMHO

[Oldog4tz]

This is my attempt to post a readable copy of this local Bay Area study - My nurse/practioner at Kaiser used it to give me a recommendation - i still needed to go to an MD, but with the kaiser note in hand

to see the article in the original use the link below - the Administrator originally posted the link - i couldn't figure out how to copy charts without violating copyright laws

Cannabis use improves retention and virological outcomes in patients treated for hepatitis C
http://www.natap.org/2006/HCV/091506_02.htm

Any way - this is an important article for those with HCV who are ALSO on treatment

Original article 1057

Cannabis use improves retention and virological outcomes
in patients treated for hepatitis C

Diana L. Sylvestrea,b, Barry J. Clementsb and Yvonne Malibub

Objectives Despite the widespread use of polypharmacy,
the management of hepatitis C virus (HCV)
treatment-related side-effects is often incomplete, and
many patients turn to cannabis for symptom relief.
Unfortunately, there are few data about cannabis use on
treatment outcomes, leaving clinicians without the data
needed to inform recommendations.

Methods To define the impact of cannabis use during HCV
treatment, we conducted a prospective observational study
of standard interferon and ribavirin treatment in 71
recovering substance users, of whom 22 (31%) used
cannabis and 49 (69%) did not.

Results Seventeen of the 71 study patients (24%)
discontinued therapy early, one cannabis user (5%) and
16 non-users (33%) (P = 0.01). Overall, 37 patients (52%)
were end-of-treatment responders, 14 (64%) cannabis
users and 23 (47%) non-users (P = 0.21). A total of 21 out of
71 (30%) had a sustained virological response: 12 of the
22 cannabis users (54%) and nine of the 49 non-users
(18%) (P = 0.009), corresponding to a post-treatment
virological relapse rate of 14% in the cannabis users and
61% in the non-users (P = 0.009). Overall, 48 (68%) were
adherent, 29 (59%) non-users and 19 (86%) cannabis
users (P = 0.03).

Conclusions Our results suggest that modest cannabis
use may offer symptomatic and virological benefit to some
patients undergoing HCV treatment by helping them
maintain adherence to the challenging medication
regimen. Although cannabis users were no more likely than non-users to take
at least 80% of the prescribed interferon or ribavirin,
they were significantly more likely to remain on HCV treatment for at least 80% of the projected treatment duration, 95 versus 67% (P = 0.01).

Eur J Gastroenterol Hepatol 18:1057–1063


Introduction
Although hepatitis C virus (HCV) treatment outcomes
have improved dramatically over the past decade, the
intolerability of interferon/ribavirin combination therapy
remains a barrier to treatment success. The majority of
patients develop significant treatment-related side effects
[1–5], with almost 80% experiencing an initial ’flulike
syndrome that includes fevers, chills, and muscle and
joint aches. Although the acute effects of treatment tend
to modulate over time, many will experience debilitating
fatigue (70–72%), headaches (66–67%), nausea (35–46%),
anorexia (19–27%), depression (21–44%), and insomnia
(30–39%) among others [3,5–7].

Many patients require the use of adjunctive pharmacological
agents for side-effect management [5,8]. These
include a spectrum of medications including antiemetics,
anti-inflammatory agents, antihistamines, sleeping pills,
antidepressants, anxiolytics, stimulants, and antipsychotics.
Unfortunately, symptom relief is often incomplete
despite the widespread use of polypharmacy, and patients
so affected may compensate by reducing their interferon
or ribavirin doses or by discontinuing treatment
altogether. Maximizing HCV treatment outcomes thus
requires a thorough familiarity with an array of successful
side-effect management strategies [5,9,10].

Faced with intolerable treatment-related side-effects that
respond inadequately to conventional medications, some
patients turn to Cannabis sativa (marijuana) for symptom
relief. Cannabis sativa contains over 400 chemical entities
[11,12], but delta-9-tetrahydrocannabinol (THC) is the
major psychoactive component. Although the majority
of studies of cannabis are observational in nature, there
is anecdotal evidence that it may have benefits in
modulating some of the common side-effects associated
with HCV treatment, including nausea [13,14], anorexia
[15,16], weight loss [17], musculoskeletal pain [18–21],
insomnia [22], anxiety [23], and mood instability [24].

However, the benefits of cannabis during HCV treatment
remain unconfirmed and concerns about its safety remain
[25–27]. Cannabinoid receptors appear to be upregulated
in hepatic myofibroblasts of human cirrhotic liver samples
[28], and smoking daily cannabis has been reported to
accelerate the progression of hepatic fibrosis in patients
with chronic HCV [29]. Cannabinoid receptors are also
present on immune cells [30], and cannabis use may
suppress a variety of immune functions, including antibody
production [31], cell proliferation [32], natural
killer cell activity [33], and macrophage function [34,35],
and also alter the production of such cytokines as
interferon gamma and tumor necrosis factor [36]. In
addition, there is a potential drug–drug interaction
between ribavirin and marijuana, as both are metabolized
by the cytochrome P450 system [37]. Obviously, the
overall benefit of cannabis in terms of side-effect
management may be outweighed by worsening histology
and impairments in virological outcomes; therefore, its
use as a potential therapeutic agent must be more clearly
defined in the setting of HCV treatment.

Although widespread restrictions limit the ease with
which these questions can be formally studied, the
pervasive use of cannabis during HCV treatment provides
a means for an observational study of its potential risks
and benefits. In the context of a prospective study of
HCV treatment in recovering heroin users maintained on
methadone we have conducted such a study, by measuring
the impact of intercurrent cannabis use on treatment
adherence, retention rates, and virological outcomes.

Methods
Study setting and eligibility

Recruitment and treatment took place at OASIS
(Organization to Achieve Solutions in Substance-Abuse),
a community-based non-profit clinic providing medical
and psychiatric treatment to substance users in Oakland,
CA. Although the clinic does not provide methadone
treatment, comprehensive primary medical and psychiatric
care services are provided on-site. All experimental
procedures were followed in accordance with the
Helsinki Declaration of 1975, as revised in 1983, and
were approved by the Ethical Review Committee (Kansas
City, Missouri, USA).

Men and women aged 18 years and older were considered
eligible if they had been maintained on methadone for a
period of 3 months or more and had a positive HCV
polymerase chain reaction (PCR). Patients with non-
HCV-related liver disease or decompensated liver disease
were excluded. Those with untreated depression were
excluded until stabilized on antidepressant treatment.

Drug use was assessed by self-report as well as by random
monthly urine toxicology testing, as per standard protocol
at the methadone clinics.

Medications

HCV treatment consisted of IFN-a 2b, 3 . 106 units
administered subcutaneously three times a week and
ribavirin capsules, 1000 mg taken orally daily in two
divided doses for patients weighing less than 165 lb, or
1200 mg daily for those weighing 165 lb or more. Patients
were initially treated for 48 weeks regardless of genotype;
however, subsequent data supporting the efficacy of 24
weeks of treatment for genotypes 2 and 3 led to a
protocol amendment that shortened the treatment course
for patients with these genotypes. Medications were self-
administered unless patients specifically requested
otherwise.

Cannabis use

The use of cannabis during study was neither endorsed
nor prohibited by study staff, and all patients obtained
their cannabis outside the construct of the study protocol.
However, because marijuana use was legalized for medical
use in the state of California, it was often obtained with
outside medical approval through local ‘cannabis clubs’.
Cannabis use was quantified by self-report, with ‘regular’
use defined as the use of cannabis every day or every
other day for a minimum duration of 4 weeks; ‘occasional’
reflected the use of less than daily quantities.

Procedures

After providing informed consent, participants completed
a questionnaire that elicited baseline demographic,
psychosocial, psychiatric, and substance use characteristics.
The duration of HCV infection was estimated as
one less than the number of years since injection drug use
was initiated. Liver biopsy was suggested but not
required, and was scored on the METAVIR scale of 0–4,
with 0, none; 1, minimal–mild; 2, mild–moderate; 3,
moderate–severe; and 4, cirrhosis.

Patients were monitored for treatment-related neutropenia,
thrombocytopenia, and hemolytic anemia using
standard published algorithms, and medication doses
were adjusted accordingly [38]. Drug and alcohol
consumption were assessed by monthly self-report
questionnaires, and monthly random urine drug test
results were obtained from the subject’s methadone
treatment program. An HCV-RNA PCR was performed at
baseline, at 6 months, at the end of treatment, and 6
months after the completion of therapy. Substance use
during HCV therapy was actively discouraged, but did not
result in treatment discontinuation unless the patient
became unreliable in attending appointments or the
clinician felt it represented a safety risk. HCV treatment
was discontinued if requested by the patient, or for
severe cytopenias, uncontrolled or worsening psychiatric
conditions, or decompensating liver disease. The protocol
was evaluated and approved by the Ethical Review
Committee, Kansas City, Missouri, USA.


Outcome measures

The primary study endpoint was sustained virological
response (SVR), as determined by undetectable levels of
HCV RNA on analysis 6 months after the completion of
therapy using the Bayer HCV-RNA branched DNA 3.0
assay, with a lower limit of detection of 550 IU/ml.
Patients were classified as sustained virological responders
at this time point if they had no detectable virus, or
as non-responders if the PCR was positive. End-oftreatment
response was defined as undetectable levels of
HCV RNA at the completion of therapy. All analyses were
performed on an intent-to-treat basis.

Adherence

Adherence to interferon was assessed by the timing of
returned empty interferon vials and by a monthly
questionnaire that detailed the number of missed doses
of medication. Adherence to ribavirin therapy was
assessed by pill counting and by query during a monthly
questionnaire. Using adherence criteria developed by
others, patients were considered adherent to the HCV
treatment regimen if they took 80% or more of the
prescribed interferon and 80% or more of the prescribed
ribavirin for at least 80% of the projected treatment
course [9].

Statistical analysis

All data were compiled in and analysed using SPSS
version 11.5.0 for Windows (SPSS Inc., Chicago, Illinois,
USA). Associations between outcome measures and
cannabis use were determined using the Student’s t or
Wilcoxon signed rank test for categorical variables.
Bivariate analysis of categorical data was performed using
the chi-square and Fisher’s exact tests. P values less than

0.05 in two-tailed comparisons were considered statistically
significant. Logistic regression was used to assess for
statistical independence among variables that showed a
univariate association with a P value of 0.20 or less.
Results
Baseline characteristics

Seventy-one patients were enrolled; 22 (31%) smoked
cannabis while undergoing HCV treatment and 49 (69%)
did not. The demographic characteristics of the study
patients are shown in Table 1. The median age was 50
years, and 43 (61%) were male, 53 (75%) Caucasian, 10
(14%) African-American, and eight (11%) Latino; there
were no differences in the demographic characteristics
between the cannabis users and non-users. The median
estimated duration of HCV exposure was 30 ± 9 years.

Forty patients (56%) had genotype 1, 29 (41%) had
genotypes 2 or 3, one patient had genotype 8a, and one
patient’s genotype was untypable. There was no difference
in the frequencies of genotypes between the
cannabis users and non-users; 30 of the non-users (61%)
and 10 of the cannabis users (48%) had genotype 1

Table 1 Demographic characteristics of study patients



Cannabis Non-users P value
users (n = 22) (n =49)
Age (median) 49.5 51 0.20
Male 15 (68%) 28 (57%) 0.44
Race
White 19 (86%) 34 (69%)
Black 1 (4%) 9 (18%) 0.20
Latino 2 (9%) 6 (12%)
Years HCV exposure 31 30 > 0.5
(median)
Genotype 1 10 (48%) 30 (61%) 0.31
Mean fibrosis stage 2.5 ± 0.4 2.7 ± 0.2 0.36
(METAVIR)

HCV, Hepatitis C virus.

(P = 0.31). Thirty patients underwent liver biopsy.
Among these, the mean METAVIR inflammation grade
was 2.4 (1.5–3.5) and the mean fibrosis stage was 2.6
(0–4). There was no significant difference in liver fibrosis
between the two groups; the mean fibrosis stage was
2.5 ± 0.4 for the cannabis users and 2.7 ± 0.2 for the nonusers
(P = 0.36). The 20 patients (28%) who had platelet
counts of less than 100 000 cells/ml were also equally
divided between the groups, comprising 29% (n = 14) of
the non-users and 27% (n = 6) of the group that used cannabis.
Forty-two patients (59%) reported a previous psychiatric
diagnosis; the majority had depression (n = 33) or
depression/anxiety (n = 6). Cannabis users were no more
likely to report a psychiatric diagnosis than non-users
(P > 0.5), and there were no differences in the rates of
antidepressant use between users and non-users during
HCV treatment (P > 0.5). Similarly, a total of 25 (35%)
used other illicit substances during HCV treatment,
including heroin, cocaine, and methamphetamine, but
this did not differ between the two groups (37% in the
cannabis non-users and 32% in the users; P > 0.5), nor
were there differences in rates of alcohol consumption
(24% in the non-users and 14% in the users; P = 0.36).

Treatment outcomes

The majority of patients, 93% (n = 66), reported at least
one treatment-related side-effect, most commonly ’flulike
symptoms, nausea, or headache, but there was no
difference in reported symptoms between the cannabis
users and non-users (P > 0.5). The association of
cannabis use with HCV treatment outcomes is shown
in Fig. 1. Seventeen of the 71 study patients (24%)
discontinued therapy before completing the full course.
Of these, 16 did not use cannabis and one was a cannabis
user. The discontinuation rate of the 49 cannabis nonusers
was 33%; it was 5% in the cannabis users (P = 0.01).
Of the 16 non-users who terminated treatment early,
eight discontinued as a result of intolerable side-effects
and four discontinued because of depression. Three of
the 16 were terminated at the discretion of the medical

provider: one because of excessive alcohol intake, one Fig. 2
because of worsening liver disease, and one because of
intractable anemia. The remaining patient in this cohort 80
relocated and was unable to obtain medications. The
single cannabis user who discontinued treatment developed
worsening liver disease and was unable to continue.






Overall, 37 of the 71 patients (52%) were end-of
treatment responders and 21 (30%) had an SVR. The
association of cannabis use with response rates is shown
in Fig. 1. Fourteen of the cannabis users (64%) and 23 of
the non-users (47%) were end-of-treatment responders

(P = 0.21). Twelve of the 22 cannabis users (54%) and
nine of the 49 non-users (18%) had an SVR, corresponding to
a post-treatment relapse rate of 14% (n = 2) with
the cannabis users and 61% (n = 14) with the non-users.
Multivariate logistic regression analysis taking sex, race,
genotype, and the use of other illicit substances into
account, revealed that this finding was statistically
significant (P = 0.009).

The association of the estimated quantity of cannabis
used with virological outcomes is shown in Fig. 2. Ten of
the 16 occasional cannabis users (62%) had an end-oftreatment
virological response compared with four of the
six regular users (67%, P > 0.5). SVR were also not
statistically different between the occasional and regular
users of cannabis, seen in two of six of the regular users
(33%) and 10 of the 16 (62%) occasional users (P = 0.35).

Adherence

The association of cannabis use with the components of
treatment adherence is shown in Fig. 3. Overall, 48 of the 71 study patients (68%) took at least 80% of the prescribed
interferon and ribavirin for at least 80% of the projected
duration of treatment, and were therefore considered
adherent. Of those, 29 did not use cannabis and 19 were
cannabis users. The corresponding adherence rates were
59% in the non-cannabis group and 86% in the cannabis
group (P = 0.03); there was no difference in adherence
between occasional users (87%) and regular users (83%)
(P >0.5).

As shown in Fig. 3, cannabis users were no more likely
than non-users to take at least 80% of the prescribed
interferon, 91 versus 76% (P = 0.2), nor were they more
likely to take at least 80% of the prescribed ribavirin, 91
versus 84% (P > 0.5). However, cannabis users were
significantly more likely than non-users to remain on
HCV treatment for at least 80% of the projected treatment course,
95 versus 67% (P = 0.01). The average
duration of HCV treatment in cannabis users was 38
weeks compared with 33 weeks for the non-users.


The results of this observational study suggest that the
use of cannabis during HCV treatment can improve adherence by
increasing the duration of time that
patients remain on therapy; this translates to reduced
rates of post-treatment virological relapse and improved
Hepatitis C treatment outcomes versus cannabis use.
Although other potential mechanisms may contribute
to its enhancement of treatment outcomes, such as
altered immunological function and improved nutritional
status, it appears that the moderate use of cannabis
during HCV treatment does not lead to deleterious
consequences.







Although its availability in the United States has been
restricted since 1937 and its benefit unconfirmed,
cannabis is frequently obtained illicitly for self-medication.
It has been used recreationally for millennia, and is the
third most commonly used drug after tobacco and alcohol
[39]. In the United States, 6.2% of individuals aged 12
years or older have used cannabis in the past month, with
4.8 million individuals using it on 20 or more days [39].
THC can produce alterations in mood, perception,
cognition, and memory [14], and studies have shown
that THC has anticonvulsive, analgesic, anti-anxiety, and
anti-emetic properties [13,14]. Clinical trials have
demonstrated that cannabinoids reduce nausea and
improve appetite in humans [15,16], and cannabis has
shown benefit in modulating the nausea of cancer
chemotherapy [40–43], multiple sclerosis-related spasticity
[44], and the wasting syndrome of HIV [17].

Progress has been made in understanding the pharmacology
of cannabinoids in humans. Of the two known
cannabinoid receptors, CB1 is responsible for the
neurological and behavioral effects of marijuana. CB1
was the first cannabinoid receptor identified [45], and is
the most abundant G-protein-coupled receptor in the
central nervous system [13]. It is also expressed on
peripheral neurons and is found abundantly in the basal
ganglia, cerebellum, and hippocampus, accounting for its
effects on motor coordination and short-term memory
[46]. It is also expressed at high concentrations on
primary afferent nociceptors of the dorsal spinal cord,
which are responsible for the ability of cannabinoids to
inhibit pain [13].

Although CB1 cannabinoid receptors mediate the central
nervous system effects of cannabinoids [46], an additional
subset of cannabinoid receptors, the CB2 receptors, is
present on immune cells [30]. The presence of these
receptors on B lymphocytes and natural killer cells
suggests that cannabinoids may impact upon the immune
response. Some studies have shown that THC can be
immunosuppressive and can impair cell-mediated immunity
[32,47,48], humoral immunity [49], and cellular
defences against a variety of infectious agents in
experimental animals [35,47,50]. There is an increased
recurrence of herpes simplex viral lesions in marijuana
smokers [51] and an altered responsiveness of human
papilloma virus to IFN-a 2a treatment [52]. Although
uncontrolled studies suggested an association between
marijuana use and the progression of HIV disease, a
recent prospective study demonstrated no evidence of
detrimental effects of cannabinoids on immune parameters
in patients with HIV [53]. The majority of studies
on the effects of cannabis have been conducted in cell
culture or on animal models with supraphysiological doses
of the compound, and their clinical relevance is unclear.

Although their potential contribution to liver disease is not
understood, both the CB1 and CB2 receptors have also
been reported to be expressed on hepatic myofibroblasts in
cirrhotic livers [28]. Activation of these receptors can lead
to cellular apoptosis, and a recent study demonstrated that
the use of cannabis on a daily basis may enhance the
progression of hepatitis fibrosis in patients with HCV [29].
By implicating these receptors as mediators of the fibrotic
process, these results raise concerns about the safety of
cannabis use in patients with HCV.

In spite of this, our results suggest that moderate
cannabis use during HCV treatment may offer significant
benefit to certain patients. Although the lack of a direct
dose response suggests that its principal contribution is
related to a non-specific improvement in the tolerability
of the challenging medication regimen, we cannot rule
out additional biological effects. We did not measure
relevant immune parameters in our patients, nor did we
assess potential differences in nutritional status. P450mediated
drug–drug interactions between cannabinoids
and ribavirin may have led to additional benefit, but these
were not assessed. However, the lack of dose response in
our study argues against specific receptor or metabolism-
related effects, and suggests instead that cannabis
exerted its benefit by non-specific improvements in
symptom management. Interestingly, because the benefits of heavy
cannabis use were less apparent, we cannot
rule out the possibility that detrimental biological or
immunological mechanisms may be relevant at higher
levels of consumption. Obviously, further study is needed.

Our study has a number of additional limitations that
warrant caution in its interpretation. First, we confined
our study to methadone-maintained patients, a population
with relatively high rates of medical and psychiatric
co-morbidity. Second, the use of additional illicit
substances was not uncommon, and although not differing
between the two cohorts, the impact of these
substances or even of methadone on study outcomes
cannot be excluded. Third, the use of marijuana was
quantified by self-report and may have introduced bias as
a result of underreporting or even overreporting. Fourth,
illicitly obtained marijuana, even that obtained through
‘cannabis clubs’, may be highly variable in its content of
bioactive compound, leaving in question a true quantitation
of the amount of cannabis that may or not be beneficial.
And finally, significant limitations are introduced
by our observational study design; however, with
legal proscriptions against cannabis use limiting its study,
the design and conduct of randomized, prospective
research studies is virtually impossible at this time.

Despite its shortcomings, this study begins to answer
some of the key questions that arise about the use of
cannabis during HCV treatment. Our results suggest that
the modest use of cannabis does not appear to impact
negatively upon HCV treatment outcomes and need not
elicit undue alarm. The widespread use of illicit cannabis
during HCV therapy highlights the inadequacies of our
current side-effect management strategies; our study
suggests that cannabis use may offer benefit for some
patients undergoing HCV treatment by helping them
maintain adherence to the frequently debilitating
medication regimen. However, the mechanisms through
which cannabis exerts its benefit are unclear, and
controlled studies may further elucidate the mechanisms
through which cannabis may impact upon clinical outcomes
during HCV treatment.

Acknowledgements

The authors would like to thank Joan Zweben, PhD,
Marc Gourevitch, MD, MPH, and Alain Litwin, MD,
MPH for helpful review of this manuscript, and Laphyne
Barrett and Emily Zubritsky for excellent technical
assistance.

Conflict of interest

DLS and BJC have received unrestricted educational grants from Roche
Pharmaceuticals and Schering Oncology Biotech.

Authors’ contributions

All authors contributed to the conduct of the study as well as manuscript
preparation.

References
1 Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events
in 11,241 patients with chronic viral hepatitis treated with alfa interferon.
J Hepatol 1996; 24:38–47.
2 Pearlman BL. Hepatitis C treatment update. Am J Med 2004; 117:
344–352.
3 Shiffman ML. Side effects of medical therapy for chronic hepatitis C.
Ann Hepatol 2004; 3:5–10.
4 Schaefer M, Schmidt F, Folwaczny C, Lorenz R, Martin G, Schindlbeck N,
et al. Adherence and mental side effects during hepatitis C treatment with
interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;
37:443–451.
5 Gish RG. Maximizing the benefits of antiviral therapy for HCV: the
advantages of treating side effects. Gastroenterol Clin North Am 2004;
33:xxiii–xxxiv.
6 Sylvestre DL, Loftis JM, Hauser P, Genser S, Cesari H, Borek N, et al.
Co-occurring hepatitis C, substance use, and psychiatric illness: treatment
issues and developing integrated models of care. J Urban Health 2004;
81:719–734.
7 Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;
345:41–52.
8 Gish RG. Treating hepatitis C: the state of the art. Gastroenterol Clin North
Am 2004; 33 (suppl 1):S1–S9.
9 McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al.
Adherence to combination therapy enhances sustained response in
genotype-1-infected patients with chronic hepatitis C. Gastroenterology
2002; 123:1061–1069.

10 Bernstein D, Kleinman L, Barker C, Revicki D, Green J. Relationship of
health-related quality of life to treatment adherence and sustained
response in chronic hepatitis C patients. Hepatology 2002; 35:
704–708.

11 Turner CE, Elsohly MA, Boeren EG. Constituents of Cannabis sativa L. XVII.
A review of the natural constituents. J Nat Prod 1980; 43:169–234.

12 Nahas G, Latour C. The human toxicity of marijuana. Med J Aust 1992;
156:495–497.

13 Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential
of cannabis. Lancet Neurol 2003; 2:291–298.

14 Dewey WL. Cannabinoid pharmacology. Pharmacol Rev 1986;
38:151–178.

15 Sallan SE, Zinberg NE, Frei E III. Antiemetic effect of delta-9tetrahydrocannabinol
in patients receiving cancer chemotherapy. N Engl
J Med 1975; 293:795–797.

16 Foltin RW, Fischman MW, Byrne MF. Effects of smoked marijuana on food
intake and body weight of humans living in a residential laboratory. Appetite
1988; 11:1–14.

17 Abrams DI. Potential interventions for HIV/AIDS wasting: an overview.
J Acquir Immune Defic Syndr 2000; 25 (suppl 1):S74–S80.

18 Holdcroft A, Smith M, Jacklin A, Hodgson H, Smith B, Newton M, Evans F.
Pain relief with oral cannabinoids in familial Mediterranean fever.
Anaesthesia 1997; 52:483–486.

19 Jain AK, Ryan JR, McMahon FG, Smith G. Evaluation of intramuscular
levonantradol and placebo in acute postoperative pain. J Clin Pharmacol
1981; 21 (suppl 8–9):320S–326S.

20 Noyes R Jr, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9tetrahydrocannabinol.
J Clin Pharmacol 1975; 15:139–143.

21 Noyes R Jr, Brunk SF, Avery DA, Canter AC. The analgesic properties of
delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975;
18:84–89.

22 Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic
applications of cannabinoids in oncology. Support Care Cancer 2003;
11:137–143.

23 Fabre LF, McLendon D. The efficacy and safety of nabilone (a synthetic
cannabinoid) in the treatment of anxiety. J Clin Pharmacol 1981; 21
(suppl 8–9):377S–382S.

24 Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in bipolar
disorder: anecdotal evidence and the need for clinical research.
J Psychoactive Drugs 1998; 30:171–177.

25 Wharry S. CMPA warns doctors of risks associated with prescribing
marijuana. Can Med Assoc J 2002; 166:83.

26 Garner D. Up in smoke: the medicinal marijuana debate. Spec Law Dig
Health Care Law 2000; issue 255:9–39.

27 Kaymakcalan S. Potential dangers of cannabis. Int J Addict 1975; 10:
721–735.

28 Julien B, Grenard P, Mallat A, Li L, Davaille J, Lotersztajn S. Activation of
cannabinoid receptors leads to apoptosis of human hepatic myofibroblasts.
Hepatology 2002; 36:388A. Cannabis and hepatitis C virus treatment Sylvestre et al. 1063

29 Hezode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafani ES, 42 Vinciguerra V, Moore T, Brennan E. Inhalation marijuana as an antiemetic for
et al. Daily cannabis smoking as a risk factor for progression of fibrosis in cancer chemotherapy. NY State J Med 1988; 88:525–527.

30 chronic hepatitis C. Hepatology 2005; 42:63–71.
Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a
43 Frytak S, Moertel CG, O’Fallon JR, Rubin J, Creagan ET, O’Connell MJ, et al.
Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer
peripheral receptor for cannabinoids. Nature 1993; 365:61–65. chemotherapy. A comparison with prochlorperazine and a placebo. Ann
31 Nahas GG, Osserman EF. Altered serum immunoglobulin concentration in Intern Med 1979; 91:825–830.
32 chronic marijuana smokers. Adv Exp Med Biol 1991; 288:25–32.
Nahas GG, Suciu-Foca N, Armand JP, Morishima A. Inhibition of cellular
44 Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A, and
the UK MS Research Group. Cannabinoids for treatment of spasticity and
33 mediated immunity in marihuana smokers. Science 1974; 183:419–420.
Cabral GA, Dove Pettit DA. Drugs and immunity: cannabinoids and their role
other symptoms related to multiple sclerosis (CAMS study): multicentre
randomised placebo-controlled trial. Lancet 2003; 362:1517–1526.
in decreased resistance to infectious disease. J Neuroimmunol 1998;
83:116–123.
45 Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a
cannabinoid receptor and functional expression of the cloned cDNA. Nature
34 Cabral GA, Vasquez, R. Effects of marijuana on macrophage function. 1990; 36:561–564.
In: Friedman HSS, Klein T, editors. Drugs of abuse, immunity and 46 Iversen L. Cannabis and the brain. Brain 2003; 126:1252–1270.
35 immunodeficiency. New York: Plenum; 1991.
Burnette-Curley D, Marciano-Cabral F, Fischer-Stenger K, Cabral GA.
47 Klein TW, Newton CA, Widen R, Friedman H. The effect of delta-9tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on Delta-9-tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of
bacillus Calmette–Guerin-activated macrophages. Int J Immunopharmacol
T-lymphocyte and B-lymphocyte mitogen responses. J Immunopharmacol
1985; 7:451–466.
1993; 15:371–382. 48 Cushman P, Khurana R. Marijuana and T lymphocyte rosettes. Clin
36 Fischer-Stenger K, Dove Pettit DA, Cabral GA. Delta 9-tetrahydrocannabinol
inhibition of tumor necrosis factor-alpha: suppression of post-translational 49
Pharmacol Ther 1976; 19:310–317.
Baczynsky WO, Zimmerman AM. Effects of delta 9-tetrahydrocannabinol,
events. J Pharmacol Exp Ther 1993; 267:1558–1565. cannabinol and cannabidiol on the immune system in mice. II. In vitro
37 Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis 1999;
19 (suppl 1):17–24.
investigation using cultured mouse splenocytes. Pharmacology 1983;
26:12–19.
38 Pianko S, McHutchison JG. Treatment of hepatitis C with interferon and 50 Lopez-Cepero M, Friedman M, Klein T, Friedman H. Tetrahydrocannabinol

39 ribavirin. J Gastroenterol Hepatol 2000; 15:581–586.
Substance Abuse and Mental Health Services Administration. National
induced suppression of macrophage spreading and phagocytic activity
in vitro. J Leukoc Biol 1986; 39:679–686.
Survey on Drug Use and Health (NSDUH). Rockville, MD, USA: Substance 51 Juel-Jensen BE. Cannabis and recurrent herpes simplex. BMJ 1972;
Abuse and Mental Health Services Administration; 2002. 4:296.
40 Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. 52 Gross G, Roussaki A, Ikenberg H, Drees N. Genital warts do not respond to
Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and systemic recombinant interferon alfa-2a treatment during cannabis
41 prochlorperazine. Cancer 1982; 50:636–645.
Chang AE, Shiling DJ, Stillman RC, Goldberg NH, Seipp CA, Barofsky I, 53
consumption. Dermatologica 1991; 183:203–207.
Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, et al.
et al. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients
receiving high-dose methotrexate. A prospective, randomized evaluation.
Short-term effects of cannabinoids in patients with HIV-1 infection:
a randomized, placebo-controlled clinical trial. Ann Intern Med 2003;
Ann Intern Med 1979; 91:819–824. 139:258–266.

[hempRules]

I went to my internal medicine doctor today, and got some unexpectadly wonderfull news. My viral count is all the way down to 7500! First I have to give credit to God, and second to medical marijuana. Over the last year I have seen my previosly consistent viral count of 20 million to 25 million drop in large chunks from 13 million, to 7 million, and now to 7500. I had blood tests every three months. My doctor and I went through all my meds, that I am taking, and discussed any change in eating or lifestyle. There was none, except that in the last year I have been smoking alot of cannabis, on a daily basis. One to two bowls with a frequency of 3 to 7 times a day. However, I didn't tell him about this. I'm going to discuss this with my medical cannabis doctor. Please understand why this is all so miraculas to me. I've had hep-c for 20 years - 11 documented, and this has NEVER happened to me before. Anyway I was wondering if anyone has had a simmular result and if it was just a fluctuation, as the disease, is known to do?

[Mindfury]

Originally Posted by hempRules

I went to my internal medicine doctor today, and got some unexpectadly wonderfull news. My viral count is all the way down to 7500! First I have to give credit to God, and second to medical marijuana. Over the last year I have seen my previosly consistent viral count of 20 million to 25 million drop in large chunks from 13 million, to 7 million, and now to 7500. I had blood tests every three months. My doctor and I went through all my meds, that I am taking, and discussed any change in eating or lifestyle. There was none, except that in the last year I have been smoking alot of cannabis, on a daily basis. One to two bowls with a frequency of 3 to 7 times a day. However, I didn't tell him about this. I'm going to discuss this with my medical cannabis doctor. Please understand why this is all so miraculas to me. I've had hep-c for 20 years - 11 documented, and this has NEVER happened to me before. Anyway I was wondering if anyone has had a simmular result and if it was just a fluctuation, as the disease, is known to do?

Thats great news. can i ask if you what treatments you were using? My last doctor didnt really know what was going on i think.They were unable to tell me what the pain in my side is. Said my liver was a little inflamed, but thats it, i'll try to find my labwork. I have no clue what my load is at. Stay well

[hempRules]

Actually, I'm not on any type of treatment, nor ever have been. My doctor did tell me that some very few individuals do fight off the virus themselves. It was a very long office visit and he just kept reviewing my chart. lol I think he was more surprised than I was. What I find amazing as well, is the whole issue of why now? I've consistently had virul counts in the tens of millions, documented, for the last ten years, since I was actually diagnosed. The only consistant thing that changed was my consumption of cannabis. It went up hep-c went down. My best scientific guess anyway. Anyway I'm going to call my cannabis doc tommorrow, and see if they know of any recent studies.

[wino]

Originally Posted by hempRules

Actually, I'm not on any type of treatment, nor ever have been. My doctor did tell me that some very few individuals do fight off the virus themselves. It was a very long office visit and he just kept reviewing my chart. lol I think he was more surprised than I was. What I find amazing as well, is the whole issue of why now? I've consistently had virul counts in the tens of millions, documented, for the last ten years, since I was actually diagnosed. The only consistant thing that changed was my consumption of cannabis. It went up hep-c went down. My best scientific guess anyway. Anyway I'm going to call my cannabis doc tommorrow, and see if they know of any recent studies.

I was diagnosed with HEP. B&C IN 1998. Had a liver biopsy, Dr. recomended interferon treatment. Looked it up on internet, med. side effects are DEVASTATING!!!! I waited 10 years(no drink, just mm) my count shot up to twenty million I did PEG-INTRON/REBETOL combination therapy from Dec. 2007 - Nov. 2008 the side effects were DEVASTATING for sure: I thank science and MEDICAL MARIJUANA for getting me thru that year (I THANK MY WIFE WITH ALL MY LOVE :Iv'e used POT for 40 years and i always will. I'm still HEP FREE.